Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

The AI and machine learning technology of Renova Health, which comprises natural language processing (NLP) and a large ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International ...

During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines ...

A new study published in the journal of Cureus showed that nearly three out of four psoriasis patients had dyslipidemia, ...

TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk ...

Review highlights how vitamin D, particularly its active form calcitriol, modulates immune responses, inflammation, and tumor ...

BALTIMORE, April 16, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...